For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

We are availabe to talk to you Monday - Friday 9am - 5pm

GDPR text - this is just a placeholder until correct text is inserted.

Have a member of our team call you back.

GDPR text - this is just a placeholder until correct text is inserted.

You can email us your enquiry by completing the form below.

Donec nisl risus, mattis ut, porttitor vitae, lobortis sagittis, lacus. Nullam neque ligula, congue at, fringilla at, consequat vitae, nulla. Nam ut felis. Curabitur imperdiet ligula a leo molestie malesuada. Praesent neque tortor, placerat accumsan, imperdiet non, iaculis at, mauris. In lacus quam, semper in, ullamcorper et, hendrerit id, pede. Nulla pretium sodales nunc.

Quisque augue quam, pulvinar in, accumsan et, pellentesque sed, ligula. Proin viverra, quam et aliquam molestie, turpis enim pellentesque eros, nec varius sem est id sapien. Aliquam at orci. Cras enim. Nam magna quam, elementum a, aliquet at, eleifend id, lacus. Donec et odio id quam laoreet suscipit.

Quisque ac ante. Aenean in neque. Suspendisse aliquet tincidunt pede. Duis mi. Morbi sapien. Cras posuere interdum nisl. Proin ac eros. Integer sit amet odio. Nullam nec velit dapibus augue condimentum egestas. Phasellus quis odio. Sed semper aliquet risus. Integer gravida vulputate sem. Praesent eu mauris. Fusce consequat congue dui. Vivamus quis metus non dui pellentesque tempor.

Davy Research

CVS Group

FY2024 results reflect a challenging year but with strong growth ahead

Sep 26 2024, 07:15 IST/BST
Colin Grant
Company Report
7 page(s)

Sectors : Pharma and healthcare

Companies : CVS Group

Ratings and price correct at time of issue.

CVS Group

Closing Price: 1120p
RATING 09/03/21
OUTPERFORM
PREVIOUS RATING N/A

Colin Grant

Analyst

DAVY VIEW

CVS had previously given many of the key figures for FY2024 to June 30th in its July trading statement. In its FY results this morning, the company outlined that it is comfortable with consensus forecasts for FY2025, which are similar to our own, and this implies around 11% EPS growth.

View full article

Download full report with analyst certification and important disclosures

Sep 26 2024, 07:15 IST/BST

Download

Davy Research

Jump to

CVS Group

FY2024 results reflect a challenging year but with strong growth ahead

CVS Group

RATING 09/03/21

Colin Grant

DAVY VIEW

Download full report with analyst certification and important disclosures